Who is sponsoring NCT02166008?

NCT02166008 is sponsored by King Chulalongkorn Memorial Hospital.

What drugs are being tested in NCT02166008?

Interventions in NCT02166008: Repamipide, Placebo.

What condition does NCT02166008 study?

NCT02166008 studies Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent.

Is NCT02166008 still recruiting?

NCT02166008 is currently completed. Last updated 26 February 2019.

Last reviewed 2019-02-26 · How we verify

NCT02166008

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study

Completed Phase 2/Phase 3 Last updated 26 February 2019

What this trial tests

Phase 2/Phase 3 trial testing Repamipide in Gastric Ulcer Induced by Anti-platelet Agent in 142 participants. Completed in 1 June 2018.

Timeline

1 July 2014

Primary endpoint
1 June 2017

1 June 2018

Quick facts

Lead sponsor	King Chulalongkorn Memorial Hospital
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	142
Start date	1 July 2014
Primary completion	1 June 2017
Estimated completion	1 June 2018
Sites	1 location across Thailand

Drugs / interventions tested

Repamipide — full drug profile →
Placebo

Conditions studied

Gastric Ulcer Induced by Anti-platelet Agent — all drugs for Gastric Ulcer Induced by Anti-platelet Agent →
Duodenal Ulcer Induced by Anti-platelet Agent — all drugs for Duodenal Ulcer Induced by Anti-platelet Agent →

Sponsor

King Chulalongkorn Memorial Hospital

Who can join

Adults 18 to 70, any sex, with Gastric Ulcer Induced by Anti-platelet Agent or Duodenal Ulcer Induced by Anti-platelet Agent. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

number of peptic ulcer by end0scopy
Time frame: 1 year

Sponsor's own description

* Primary objective : To evaluate the efficacy of Rapamide in peptic ulcer prevention in patients taking dual antiplatelet agents * Study Design: Single center, double-blind, randomized-control trial study * Study drug: Repamipide vs. placebo * Assessment criteria The patients will be discharged from the study when one of the followings occurred, 1. Peptic ulcer from upper endoscopy at 3 and 6 month follow up 2. Clinical of upper gastrointestinal bleeding with peptic ulcer from upper endoscopy 3. Anemia by CBC at 1,3 ,6,12 month with peptic ulcer from upper endoscopy 4. Evidence of recurrent myocardial infarction from stent thrombosis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Pittayanon R, Piyachaturawat P, Rerknimitr R, Prueksapanich P, et al · · 2019 · cited 1× · PMID 30919492 · DOI 10.1111/jgh.14671

Verify or expand the search:

Other King Chulalongkorn Memorial Hospital trials

Trials by the same sponsor.

NCT07171853 — The Carbon Footprint Study of Colonoscopy · recruiting
NCT07261228 — The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper · recruiting
NCT06906835 — Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis · NA · recruiting
NCT06030609 — The Comparison Between Ringer Lactate Solution and Normal Saline With Dextrose Water in Post-Operative Period of Kidney · Phase 3 · completed
NCT06288828 — The Efficacy of Aerobic Exercise Training on Autonomic Nervous System and Endothelial Function in Patients with Compensa · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02166008 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King Chulalongkorn Memorial Hospital
Last refreshed: 26 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02166008.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing